Cargando…

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist

Exendin-4 is a strong therapeutic candidate for the treatment of metabolic syndrome. Related receptor agonist drugs have been on the market since 2005. However, technical limitations and the pain caused by subcutaneous injection have severely limited patient compliance. The goal of the study is to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sai, Wenbo, Tian, Hong, Yang, Kangmin, Tang, Daoqi, Bao, Jinxiao, Ge, Yang, Song, Xiaoda, Zhang, Yu, Luo, Cheng, Gao, Xiangdong, Yao, Wenbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372594/ https://www.ncbi.nlm.nih.gov/pubmed/28282854 http://dx.doi.org/10.3390/ijms18030578

Ejemplares similares

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Indirect Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Peripheral Circadian Clocks in Mice
por: Ando, Hitoshi, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference
por: Zhu, Changliang, et al.
Publicado: (2021)

The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia
por: Chen, Fangzhe, et al.
Publicado: (2016)

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia
por: Teramoto, Shinichiro, et al.
Publicado: (2011)

Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice
por: Zhu, Changliang, et al.
Publicado: (2022)

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
por: Arakawa, Masayuki, et al.
Publicado: (2010)

Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
por: Barrera, Jason G., et al.
Publicado: (2009)

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia
por: Yanay, Ofer, et al.
Publicado: (2015)

Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
por: Kim, Soojin, et al.
Publicado: (2017)

Unexpected Trypsin Cleavage at Ubiquitinated Lysines
por: Burke, Meghan C., et al.
Publicado: (2015)

Glucagon-like peptide-1 analogue exendin-4 modulates serotonin transporter expression in intestinal epithelial cells
por: Cui, Xiufang, et al.
Publicado: (2020)

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret
por: Lu, Zengbing, et al.
Publicado: (2014)

Role of Renal Sympathetic Nerves in GLP‐1 (Glucagon‐Like Peptide‐1) Receptor Agonist Exendin‐4‐Mediated Diuresis and Natriuresis in Diet‐Induced Obese Rats
por: Liu, Xuefei, et al.
Publicado: (2021)

Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin
por: Guo, X.-L., et al.
Publicado: (2008)

Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
por: Yamamoto, Koji, et al.
Publicado: (2013)

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

The GLP-1 agonist, exendin-4, stimulates LH secretion in female sheep
por: Simpson, Elizabeth M, et al.
Publicado: (2023)

In Vitro Metabolic Stability of Exendin-4: Pharmacokinetics and Identification of Cleavage Products
por: Liao, Sha, et al.
Publicado: (2015)

Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression
por: YI, BO, et al.
Publicado: (2014)

The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages
por: Shen, Wei-Ren, et al.
Publicado: (2018)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

Correction: In Vitro Metabolic Stability of Exendin-4: Pharmacokinetics and Identification of Cleavage Products
Publicado: (2015)

An Antibacterial Peptide with High Resistance to Trypsin Obtained by Substituting d-Amino Acids for Trypsin Cleavage Sites
por: Zhao, Xiaoou, et al.
Publicado: (2021)

(64)Cu Labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 Receptor Expression
por: Wu, Zhanhong, et al.
Publicado: (2014)

Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats
por: Chen, Yen-Cheng, et al.
Publicado: (2017)

Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4
por: Tinsley, Ian C., et al.
Publicado: (2021)

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
por: Zhang, Ling-Yu, et al.
Publicado: (2021)

Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake
por: Läppchen, Tilman, et al.
Publicado: (2017)

Nonspecific cleavages arising from reconstitution of trypsin under mildly acidic conditions
por: Niu, Ben, et al.
Publicado: (2020)

Combination of Obesity and High-Fat Feeding Diminishes Sensitivity to GLP-1R Agonist Exendin-4
por: Duca, Frank A., et al.
Publicado: (2013)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Anti‐inflammatory effects of exendin‐4, a glucagon‐like peptide‐1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
por: He, Lan, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice
por: Zhu, Changliang, et al.
Publicado: (2021)

Trypsin cleavage sites are highly unlikely to occur in celiac-causing restricted epitopes
por: Herman, Rod A., et al.
Publicado: (2019)

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
por: Song, Rui, et al.
Publicado: (2022)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6id8roip1c4s1rocea139nuh3d